Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.2.1.117 - amygdalin beta-glucosidase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis
Effect of acarbose on acute acidosis.
Acquired Immunodeficiency Syndrome
Computer-aided molecular design of novel glucosidase inhibitors for AIDS treatment.
amygdalin beta-glucosidase deficiency
Alpha glucosidases in white blood cells, with reference to the detection of acid alpha 1-4 glucosidase deficiency.
Diagnosing Gaucher disease: an on-going need for increased awareness amongst haematologists.
Extensive genetic heterogeneity in patients with acid alpha glucosidase deficiency as detected by abnormalities of DNA and mRNA.
Late familial pseudo-myopathic muscular glycogenosis with alpha 1,4 glucosidase deficiency. Morphological, histoenzymological and biochemical approach.
Molecular features of 23 patients with glycogen storage disease type III in Turkey: a novel mutation p.R1147G associated with isolated glucosidase deficiency, along with 9 AGL mutations.
The brain in late-onset glycogenosis II: a structural and functional MRI study.
White blood cells and the diagnosis of alpha-glucosidase deficiency.
[Chronic respiratory failure in a case with juvenile-onset acid alpha-glucosidase deficiency; successful therapy with nasal intermittent positive pressure ventilation (NIPPV)]
[Ichthyosiform scaling in alpha-1,4-glucosidase deficiency]
[Report of a case of Gaucher's disease in adult]
[Therapeutic objectives in Gaucher disease]
Atherosclerosis
Influence of acarbose (a glucosidase inhibitor) on experimental atherosclerosis in the rabbit.
Azoospermia
Seminal plasma hexosaminidase in patients with normal and abnormal spermograms.
Bronchopneumonia
A severe form of non-classic Pompe's disease with normal creatinine kinase level.
Cardiomyopathies
Juvenile acid maltase deficiency presenting as paravertebral pseudotumour.
Cardiovascular Diseases
Functional Foods and Nutraceuticals as Dietary Intervention in Chronic Diseases; Novel Perspectives for Health Promotion and Disease Prevention.
Colonic Neoplasms
Ataxin-10 is part of a cachexokine cocktail triggering cardiac metabolic dysfunction in cancer cachexia.
Connective Tissue Diseases
Excretion of glucose-containing oligosaccharides in urines of orthopedic patients.
COVID-19
Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study.
Cystic Fibrosis
Alterations in specific activity of lysosomal alpha-glucosidase in cystic fibrosis.
Dehydration
Postharvest ethylene treatment affects berry dehydration, polyphenol and anthocyanin content by increasing the activity of cell wall enzymes in Aleatico wine grape
Dementia
Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease.
Glucocerebrosidase Deficiency in Drosophila Results in ?-Synuclein-Independent Protein Aggregation and Neurodegeneration.
Glucocerebrosidase reduces the spread of protein aggregation in a Drosophila melanogaster model of neurodegeneration by regulating proteins trafficked by extracellular vesicles.
Increased glucocerebrosidase expression and activity in preeclamptic placenta.
Dengue
Antiviral activities of sulfonium-ion glucosidase inhibitors and 5-thiomannosylamine disaccharide derivatives against dengue virus.
Diabetes Mellitus
A case of nephrogenic diabetes insipidus caused by obstructive uropathy due to prostate cancer.
Alpha glucosidase inhibition by stem extract of Tinospora cordifolia.
Antidiabetic potential of Asparagus racemosus Willd leaf extracts through inhibition of ?-amylase and ?-glucosidase.
Antidiabetic potential of polyoxotungstates: in vitro and in vivo studies.
Chickpea (Cicer arietinum L.) Lectin Exhibit Inhibition of ACE-I, ?-amylase and ?-glucosidase Activity.
Food-grade mulberry powder enriched with 1-deoxynojirimycin suppresses the elevation of postprandial blood glucose in humans.
Long-term treatment in diabetics with acarbose, a glucosidase inhibitor: efficacy, tolerability and effect on GI hormones.
Oral diabetic medications and the geriatric patient.
Reappraisal and perspectives of clinical drug-drug interaction potential of ?-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus.
The effect of new alpha-glucosidase inhibitors (BAY m 1099 and BAY o 1248) on meal-stimulated increases in glucose and insulin levels in man.
[Acarbose, a glucosidase inhibitor: a new therapeutic principle in diabetes mellitus]
[Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study]
Diabetes Mellitus, Type 2
Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus.
Antidiabetic potential of Asparagus racemosus Willd leaf extracts through inhibition of ?-amylase and ?-glucosidase.
Change of Oral to Topical Corticosteroid Therapy Exacerbated Glucose Tolerance in a Patient with Plaque Psoriasis.
Chemometrics Optimized Extraction Procedures, Phytosynergistic Blending and in vitro Screening of Natural Enzyme Inhibitors Amongst Leaves of Tulsi, Banyan and Jamun.
Comparison of Placebo Effect between Asian and Caucasian Type 2 Diabetic Patients: A Meta-Analysis.
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
Comparisons of the efficacy of alpha glucosidase inhibitors on type 2 diabetes patients between Asian and Caucasian.
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
Kinetics of ?-glucosidase inhibition by different fractions of three species of Labiatae extracts: a new diabetes treatment model.
New glucosidase inhibitors from an ayurvedic herbal treatment for type 2 diabetes: structures and inhibition of human intestinal maltase-glucoamylase with compounds from Salacia reticulata.
Oral antidiabetic agents as cardiovascular drugs.
Reappraisal and perspectives of clinical drug-drug interaction potential of ?-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study.
Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus.
The treatment of type 2 diabetes mellitus in youth : which therapies?
[Effect of glucosidase inhibitor, Bay g 5421 (acarbose), on the blood glucose in obese diabetic patients ty pe 2 (NIDDM) (author's transl)]
[Oral antidiabetic drugs in 2003]
Diabetic Cardiomyopathies
Medicinal chemistry of drugs used in diabetic cardiomyopathy.
Epididymitis
The evaluation of markers of prostatic function.
Gangliosidosis, GM1
GM1 gangliosidosis type 2 in two siblings.
Gaucher Disease
Beta-glucosidase activity in liver, spleen and brain in acute neuropathic Gaucher disease.
Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones.
Clinicogenetic Profile, Treatment Modalities, and Mortality Predictors of Gaucher Disease: A 15-Year Retrospective Study.
Gaucher disease in Syrian children: common mutations identification, and clinical futures.
Gaucher Disease Presenting in an Adult with Intracerebral Bleed.
Gaucher disease type 1: Unexpected diagnosis in a 75-year old patient presenting with splenomegaly.
Glucocerebrosidase Deficiency in Drosophila Results in ?-Synuclein-Independent Protein Aggregation and Neurodegeneration.
Glucosidase acid beta gene mutations in Egyptian children with Gaucher disease and relation to disease phenotypes.
Increased glucocerebrosidase expression and activity in preeclamptic placenta.
Lentiviral Gene Therapy Using Cellular Promoters Cures Type 1 Gaucher Disease in Mice.
Murine models of acute neuronopathic Gaucher disease.
Profile of eliglustat tartrate in the management of Gaucher disease.
Retroviral-mediated transfer of the human glucocerebrosidase gene into cultured Gaucher bone marrow.
Three mutations of adult type 1 Gaucher disease found in a Chinese patient: A case report.
[Gaucher's disease: results of enzymatic treatment with beta glucosidase acid]
[Therapeutic objectives in Gaucher disease]
Genetic Diseases, Inborn
Effects of lysosomal biotherapeutic recombinant protein expression on cell stress and protease and general host cell protein release in Chinese hamster ovary cells.
glucan 1,4-alpha-glucosidase deficiency
Juvenile acid maltase deficiency presenting as paravertebral pseudotumour.
Multiple muscles in the AMD quail can be "cross-corrected" of pathologic glycogen accumulation after intravenous injection of an [E1-, polymerase-] adenovirus vector encoding human acid-alpha-glucosidase.
Glucose Intolerance
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
SGLT2 inhibition alleviated hyperglycemia, glucose intolerance, and dumping syndrome-like symptoms in a patient with glycogen storage disease type Ia: a case report.
Glycogen Storage Disease
Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.
Auditory system involvement in late onset Pompe disease: A study of 20 Italian patients.
Cardiac involvement in adults with Pompe disease.
Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
Exercise, nutrition and enzyme replacement therapy are efficacious in adult Pompe patients: report from EPOC Consortium.
Extensive genetic heterogeneity in patients with acid alpha glucosidase deficiency as detected by abnormalities of DNA and mRNA.
Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
Identification of a missense mutation in an adult-onset patient with glycogenosis type II expressing only one allele.
Identification of a missense mutation in one allele of a patient with Pompe disease, and use of endonuclease digestion of PCR-amplified RNA to demonstrate lack of mRNA expression from the second allele.
Identification of four novel mutations in the alpha glucosidase gene in five Italian patients with infantile onset glycogen storage disease type II.
Identification of the promoter region and gene expression for human acid alpha glucosidase.
Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
Infantile hypotonia with failure to thrive.
Isolation and partial characterization of the structural gene for human acid alpha glucosidase.
Juvenile acid maltase deficiency presenting as paravertebral pseudotumour.
Late familial pseudo-myopathic muscular glycogenosis with alpha 1,4 glucosidase deficiency. Morphological, histoenzymological and biochemical approach.
Late Onset Glycogen Storage Disease Type II: Pitfalls in the Diagnosis.
Molecular features of 23 patients with glycogen storage disease type III in Turkey: a novel mutation p.R1147G associated with isolated glucosidase deficiency, along with 9 AGL mutations.
Production of a Functional Human Acid Maltase in Tobacco Seeds: Biochemical Analysis, Uptake by Human GSDII Cells, and In Vivo Studies in GAA Knockout Mice.
Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease.
The brain in late-onset glycogenosis II: a structural and functional MRI study.
The identification of five novel mutations in the lysosomal acid a-(1-4) glucosidase gene from patients with glycogen storage disease type II. Mutations in brief no. 134. Online.
[Clinical observation on human alpha glucosidase in treatment of five patients with glycogen storage disease ?].
[Ichthyosiform scaling in alpha-1,4-glucosidase deficiency]
Glycogen Storage Disease Type II
A randomized study of alglucosidase alfa in late-onset Pompe's disease.
A severe form of non-classic Pompe's disease with normal creatinine kinase level.
AAV Gene Therapy Utilizing Glycosylation-Independent Lysosomal Targeting Tagged GAA in the Hypoglossal Motor System of Pompe Mice.
Absolute quantification of the total and antidrug antibody-bound concentrations of recombinant human ?-glucosidase in human plasma using protein G extraction and LC-MS/MS.
Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.
Alpha Glucosidase Assay on Dried Blood Spot in the Early Diagnosis of Infantile Pompe Disease.
Alpha-1,4 glucosidase activity in Pompe's disease.
An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.
Apical Hypertrophic Cardiomyopathy in an Infant: First Presentation of Pompe's Disease.
Auditory system involvement in late onset Pompe disease: A study of 20 Italian patients.
Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.
Cardiac involvement in adults with Pompe disease.
Cardiomyopathy in Pompe's disease.
Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.
Deferoxamine mesylate improves splicing and GAA activity of the common c.-32-13T>G allele in late-onset PD patient fibroblasts.
Deficiency of acid alpha glucosidase in the urine of patients with Pompe's disease.
Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa.
Diagnosing lysosomal storage disorders: Pompe disease.
Diagnostic challenges for Pompe disease: an under-recognized cause of floppy baby syndrome.
Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up.
Effects of lysosomal biotherapeutic recombinant protein expression on cell stress and protease and general host cell protein release in Chinese hamster ovary cells.
Exercise, nutrition and enzyme replacement therapy are efficacious in adult Pompe patients: report from EPOC Consortium.
Extensive genetic heterogeneity in patients with acid alpha glucosidase deficiency as detected by abnormalities of DNA and mRNA.
GENERALIZED GLYCOGENOSIS. REPORT OF A CASE WITH DEFICIENCY OF ALPHA GLUCOSIDASE.
Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease.
Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature.
Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
Identification and characterization of aberrant GAA pre-mRNA splicing in pompe disease using a generic approach.
Identification of a missense mutation in an adult-onset patient with glycogenosis type II expressing only one allele.
Identification of a missense mutation in one allele of a patient with Pompe disease, and use of endonuclease digestion of PCR-amplified RNA to demonstrate lack of mRNA expression from the second allele.
Identification of four novel mutations in the alpha glucosidase gene in five Italian patients with infantile onset glycogen storage disease type II.
Identification of the promoter region and gene expression for human acid alpha glucosidase.
Immunomodulatory, liver depot gene therapy for Pompe disease.
Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
Infantile hypotonia with failure to thrive.
Isolation and partial characterization of the structural gene for human acid alpha glucosidase.
Juvenile acid maltase deficiency presenting as paravertebral pseudotumour.
Late Onset Glycogen Storage Disease Type II: Pitfalls in the Diagnosis.
Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.
Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker.
Longitudinal follow-up to evaluate speech disorders in early-treated patients with infantile-onset Pompe disease.
Mitochondrial Variants in Pompe Disease: A Comparison between Classic and Non-Classic Forms.
Multiple muscles in the AMD quail can be "cross-corrected" of pathologic glycogen accumulation after intravenous injection of an [E1-, polymerase-] adenovirus vector encoding human acid-alpha-glucosidase.
Newborn screening for Pompe disease in Japan.
Next generation deep sequencing corrects diagnostic pitfalls of traditional molecular approach in a patient with prenatal onset of Pompe disease.
Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.
Peripheral nerve and neuromuscular junction pathology in Pompe disease.
Phosphatidylserine Is Not Just a Cleanup Crew but Also a Well-Meaning Teacher.
Pompe disease: literature review and case series.
Production of a Functional Human Acid Maltase in Tobacco Seeds: Biochemical Analysis, Uptake by Human GSDII Cells, and In Vivo Studies in GAA Knockout Mice.
Production of Human Acid-Alpha Glucosidase With a Paucimannose Structure by Glycoengineered Arabidopsis Cell Culture.
Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
Quality of life and its contributors among adults with late-onset Pompe disease in China.
Restoring the regenerative balance in neuromuscular disorders: satellite cell activation as therapeutic target in Pompe disease.
Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease.
Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease.
Sustained Correction of Motoneuron Histopathology Following Intramuscular Delivery of AAV in Pompe Mice.
Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease.
Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
The brain in late-onset glycogenosis II: a structural and functional MRI study.
The identification of five novel mutations in the lysosomal acid a-(1-4) glucosidase gene from patients with glycogen storage disease type II. Mutations in brief no. 134. Online.
Therapeutic Benefit of Autophagy Modulation in Pompe Disease.
When more is less: excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease.
[Chronic respiratory failure in a case with juvenile-onset acid alpha-glucosidase deficiency; successful therapy with nasal intermittent positive pressure ventilation (NIPPV)]
[Pompe disease is a differential diagnosis in case of reduced physical capacity and abnormal muscular fatigue.]
Glycogen Storage Disease Type III
Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.
Molecular features of 23 patients with glycogen storage disease type III in Turkey: a novel mutation p.R1147G associated with isolated glucosidase deficiency, along with 9 AGL mutations.
Hepatitis
Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks.
Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents.
Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs.
Hepatitis B
alpha-Glucosidase inhibitors have a prolonged antiviral effect against hepatitis B virus through the sustained inhibition of the large and middle envelope glycoproteins.
Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks.
Glucosidase inhibitors as antiviral agents for hepatitis B and C.
Hepatitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme.
Hepatitis B virus MHBs antigen is selectively sensitive to glucosidase-mediated processing in the endoplasmic reticulum.
Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs.
Hepatitis C
Alpha-glucosidase inhibitors as potential broad based anti-viral agents.
Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents.
Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs.
Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors.
Hepatitis C, Chronic
Inhibitors of endoplasmic reticulum alpha-glucosidases potently suppress hepatitis C virus virion assembly and release.
HIV Infections
Activity of glucosidase inhibitors against HIV infections.
Hyperacusis
GM1 gangliosidosis type 2 in two siblings.
Hypergammaglobulinemia
[Report of a case of Gaucher's disease in adult]
Hyperglycemia
Antidiabetic potential of Asparagus racemosus Willd leaf extracts through inhibition of ?-amylase and ?-glucosidase.
Antidiabetic property of Symplocos cochinchinensis is mediated by inhibition of alpha glucosidase and enhanced insulin sensitivity.
Beneficial effect of flax seeds in streptozotocin (STZ) induced diabetic mice: isolation of active fraction having islet regenerative and glucosidase inhibitory properties.
Chickpea (Cicer arietinum L.) Lectin Exhibit Inhibition of ACE-I, ?-amylase and ?-glucosidase Activity.
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Effects of insulin and other antihyperglycemic agents on lipid profiles of patients with diabetes.
Efficacy and Cardiovascular Safety of Alpha Glucosidase Inhibitors.
Genetic engineering of Lactococcus lactis to produce an amylase inhibitor for development of an anti-diabetes biodrug.
In-vitro ? amylase and glycosidase inhibitory effect of ethanolic extract of antiasthmatic drug - Shirishadi.
Islet protective and insulin secretion property of Murraya koenigii and Ocimum tenuflorum in streptozotocin-induced diabetic mice.
Recent Trends in Therapeutic Approaches for Diabetes Management: A Comprehensive Update.
Seed Proteomic Profiles of Three Paeonia Varieties and Evaluation of Peony Seed Protein as a Food Product.
The administration of nonmetabolizable glucose analogues fails to suppress the development of glycogen autophagy in newborn rat hepatocytes.
[New therapies in type 2 diabetes]
[Oral antidiabetic agents: recent aspects]
[Recent research advances of 1-deoxynojirimycin and its derivatives].
Hypersensitivity
Allergic and intolerance reactions to wine.
Generation of transgenic rice with reduced content of major and novel high molecular weight allergens.
Hypoglycemia
Use of the alpha glucosidase inhibitor acarbose in patients with 'Middleton syndrome': normal gastric anatomy but with accelerated gastric emptying causing postprandial reactive hypoglycemia and diarrhea.
Infections
DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials.
Glucosidase inhibitors for treatment of HIV-1 infection.
Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic.
Mechanism of action of N-butyl deoxynojirimycin in inhibiting HIV-1 infection and activity in combination with nucleoside analogs.
Seminal alpha-glucosidase activity as a marker of epididymal pathology in nonazoospermic men consulting for infertility.
Transcriptome Analysis of Apple Leaves in Response to Powdery Mildew (Podosphaera leucotricha) Infection.
Infertility
Seminal alpha-glucosidase activity as a marker of epididymal pathology in nonazoospermic men consulting for infertility.
Influenza, Human
Effect of glycosylation and glucose trimming inhibitors on the influenza A virus glycoproteins.
Insulin Resistance
A quick overview on some aspects of endocrinological and therapeutic effects of Berberis vulgaris L.
Antidiabetic property of Symplocos cochinchinensis is mediated by inhibition of alpha glucosidase and enhanced insulin sensitivity.
Liver Cirrhosis
Effects of the glucosidase inhibitor acarbose in patients with liver cirrhosis.
Liver Diseases
A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation.
Mutations in GANAB, Encoding the Glucosidase II? Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.
Lymphoma
Characterization of endomannosidase inhibitors and evaluation of their effect on N-linked oligosaccharide processing during glycoprotein biosynthesis.
Characterization of the endomannosidase pathway for the processing of N-linked oligosaccharides in glucosidase II-deficient and parent mouse lymphoma cells.
Gaucher disease type 1: Unexpected diagnosis in a 75-year old patient presenting with splenomegaly.
N-linked oligosaccharide processing enzyme glucosidase II produces 1,5-anhydrofructose as a side product.
Lysosomal Storage Diseases
Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.
Synthesis of novel mono and bis-indole conduritol derivatives and their ?/?-glycosidase inhibitory effects.
Melanoma
Effect of inhibitors of N-linked oligosaccharide processing on the cell surface expression of a melanoma integrin.
Post-translational addition of chondroitin sulfate glycosaminoglycans. Role of N-linked oligosaccharide addition, trimming, and processing.
Rapid and reversible inhibition of tyrosinase activity by glucosidase inhibitors in human melanoma cells.
Metabolic Syndrome
In vitro Antioxidant, Anti-inflammatory, Anti-metabolic Syndrome, Antimicrobial, and Anticancer Effect of Phenolic Acids Isolated from Fresh Lovage Leaves [Levisticum officinale Koch] Elicited with Jasmonic Acid and Yeast Extract.
Mucolipidoses
Prenatal diagnosis of I-cell disease.
Mucopolysaccharidoses
GM1 gangliosidosis type 2 in two siblings.
Muscular Diseases
A randomized study of alglucosidase alfa in late-onset Pompe's disease.
Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa.
Efficacy of cornstarch therapy in type III glycogen-storage disease.
Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature.
Identification of patients with Pompé disease using routine pathology results: PATHFINDER (creatine kinase) study.
Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.
Pompe disease: literature review and case series.
Restoring the regenerative balance in neuromuscular disorders: satellite cell activation as therapeutic target in Pompe disease.
Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease.
[Pompe disease is a differential diagnosis in case of reduced physical capacity and abnormal muscular fatigue.]
Muscular Dystrophies
Juvenile acid maltase deficiency presenting as paravertebral pseudotumour.
Neoplasms
A Diabetes Pay-for-Performance Program and Risks of Cancer Incidence and Death in Patients With Type 2 Diabetes in Taiwan.
Changes in the activities of jejunal glucosidases in experimental intestinal tumorigenesis induced by 1,2 dimethylhydrazine in rats fed different diets.
Inhibition of DNA synthesis by a small-cell lung carcinoma-derived protein.
Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies.
Synthesis of novel mono and bis-indole conduritol derivatives and their ?/?-glycosidase inhibitory effects.
The alpha-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth.
Neuroblastoma
Uptake by neuroblastoma cells of glucosylceramide, glucosylceramide glucosidase, its stimulator protein, and phosphatidylserine.
Neurodegenerative Diseases
Functional Foods and Nutraceuticals as Dietary Intervention in Chronic Diseases; Novel Perspectives for Health Promotion and Disease Prevention.
Obesity
Effects of a glucosidase inhibitor (acarbose, BAY g 5421) on the development of obesity and food motivated behavior in Zucker (fafa) rats.
Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia.
Miglitol prevents diet-induced obesity by stimulating brown adipose tissue and energy expenditure independent of preventing the digestion of carbohydrates.
Osteoporosis
An update on therapies for the treatment of diabetes-induced osteoporosis.
Overweight
Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis.
Parkinson Disease
Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease.
GBA-Associated Parkinson's Disease: Progression in a Deep Brain Stimulation Cohort.
Glucocerebrosidase Deficiency in Drosophila Results in ?-Synuclein-Independent Protein Aggregation and Neurodegeneration.
Parkinsonian Disorders
Increased glucocerebrosidase expression and activity in preeclamptic placenta.
Polycystic Kidney Diseases
A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation.
Mutations in GANAB, Encoding the Glucosidase II? Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.
Polyuria
A case of nephrogenic diabetes insipidus caused by obstructive uropathy due to prostate cancer.
Premature Ejaculation
[Semen biochemical markers and their significance in the patients with premature ejaculation]
Prostatitis
The evaluation of markers of prostatic function.
Proteinuria
Hypotensive and renal effects of captopril.
pullulanase deficiency
Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathy.
Respiratory Insufficiency
[Chronic respiratory failure in a case with juvenile-onset acid alpha-glucosidase deficiency; successful therapy with nasal intermittent positive pressure ventilation (NIPPV)]
Retinal Degeneration
GM1 gangliosidosis type 2 in two siblings.
Speech Disorders
Longitudinal follow-up to evaluate speech disorders in early-treated patients with infantile-onset Pompe disease.
Teratocarcinoma
Transfer of nonglucosylated oligosaccharide from lipid to protein in a mammalian cell.
Thrombocytopenia
[Report of a case of Gaucher's disease in adult]
Thymoma
Unique expression of major histocompatibility complex class I proteins in the absence of glucose trimming and calnexin association.
Urticaria
Influence of Nesting Habitats on the Gut Enzymes Activity and Heavy Metal Composition of Apis mellifera andersonii L. (Hymenoptera: Apidae)
Vaccinia
Effect of a glucosidase inhibitor on the bioactivity and immunoreactivity of human immunodeficiency virus type 1 envelope glycoprotein.
Varicocele
Markers of accessory sex glands function in men with varicocele, relationship with seminal parameters.
Virus Diseases
Synthesis of novel mono and bis-indole conduritol derivatives and their ?/?-glycosidase inhibitory effects.